New Zealand Cannabis Producers Seek Regulatory Reforms to Secure High Value Exports

New Zealand cannabis producers seek regulatory reforms to boost local processing and high value exports as major manufacturers like Helius Therapeutics exit.

By: AXL Media

Published: Apr 17, 2026, 8:13 AM EDT

Source: RNZ Pacific

Local Sector Faces Contraction Amid Manufacturing Hurdles

The New Zealand medicinal cannabis landscape is undergoing a difficult transition period marked by the exit of several key market participants. Most recently, Helius Therapeutics announced the closure of its East Tāmaki facility, a move that impacts 65 employees and removes one of the nation's few certified processing sites from the ecosystem. This follows the previous closures of other industry players like Greenfern Industries and Cannasouth, highlighting a broader trend of domestic instability.

The Value Add Gap in Domestic Production

A primary tension within the sector involves the "Good Manufacturing Practice" (GMP) certification required for advanced product formulation. Currently, many New Zealand growers are restricted to exporting raw cannabis flower or "bud" rather than processed, high value goods like capsules or oils. This creates a strategic disadvantage where New Zealand provides the raw ingredients while offshore manufacturers in countries like Canada capture the significant profit margins associated with finished pharmaceutical products.

Transformative Analysis: This dynamic mirrors the traditional challenges faced by New Zealand’s primary sectors, such as dairy or wool, where the country often acts as a raw material supplier. To move up the value chain, the cannabis sector requires a decentralization of the GMP burden, allowing growers to focus on cultivation while utilizing centralized, certified hubs for finished product manufacturing.

Strategic Pivots and the Rise of Export Focus